1h Free Analyst Time
5' Nucleotidase - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
According to the recently published report '5' Nucleotidase - Pipeline Review, H1 2020'; 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 34 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.
The report '5' Nucleotidase - Pipeline Review, H1 2020' outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 16 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Solid Tumor, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Melanoma, Triple-Negative Breast Cancer (TNBC), Breast Cancer, Colorectal Cancer, Kidney Cancer (Renal Cell Cancer), Prostate Cancer, Colon Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Lung Cancer, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Lung Cancer, Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Development
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Assessment
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies Involved in Therapeutics Development
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products
- 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indications, H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..1)
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020 (Contd..2), H1 2020
- Products under Development by Companies, H1 2020 (Contd..3), H1 2020
- Products under Development by Companies, H1 2020 (Contd..4), H1 2020
- Number of Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by Akeso Inc, H1 2020
- Pipeline by Aprilbio Co Ltd, H1 2020
- Pipeline by Arcus Biosciences Inc, H1 2020
- Pipeline by AstraZeneca Plc, H1 2020
- Pipeline by Aurigene Discovery Technologies Ltd, H1 2020
- Pipeline by Bristol-Myers Squibb Co, H1 2020
- Pipeline by Calithera Biosciences Inc, H1 2020
- Pipeline by Corvus Pharmaceuticals Inc, H1 2020
- Pipeline by Eli Lilly and Co, H1 2020
- Pipeline by Eternity Bioscience Inc, H1 2020
- Pipeline by Evotec SE, H1 2020
- Pipeline by Gilead Sciences Inc, H1 2020
- Pipeline by Harbour BioMed, H1 2020
- Pipeline by I-Mab Biopharma Co Ltd, H1 2020
- Pipeline by Innate Pharma SA, H1 2020
- Pipeline by InteRNA Technologies BV, H1 2020
- Pipeline by iOnctura SA, H1 2020
- Pipeline by Merck & Co Inc, H1 2020
- Pipeline by Novartis AG, H1 2020
- Pipeline by ORIC Pharmaceuticals Inc, H1 2020
- Pipeline by Phanes Therapeutics Inc, H1 2020
- Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H1 2020
- Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
- Pipeline by Shanghai Henlius Biotech Inc, H1 2020
- Pipeline by Xcella Biosciences Inc, H1 2020
- Dormant Projects, H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Routes of Administration, H1 2020
- Number of Products by Stage and Routes of Administration, H1 2020
- Number of Products by Molecule Types, H1 2020
- Number of Products by Stage and Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akeso Inc
- Aprilbio Co Ltd
- Arcus Biosciences Inc
- AstraZeneca Plc
- Aurigene Discovery Technologies Ltd
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- Corvus Pharmaceuticals Inc
- Eli Lilly and Co
- Eternity Bioscience Inc
- Evotec SE
- Gilead Sciences Inc
- Harbour BioMed
- I-Mab Biopharma Co Ltd
- Innate Pharma SA
- InteRNA Technologies BV
- iOnctura SA
- Merck & Co Inc
- Novartis AG
- ORIC Pharmaceuticals Inc
- Phanes Therapeutics Inc
- Secarna Pharmaceuticals GmbH & Co. KG
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Henlius Biotech Inc
- Xcella Biosciences Inc
